# ARTURO CESARO, M.D.

## CURRICULUM VITÆ

### Index of contents


| | |
|---|---|
| 1. Personal data | 2 |
| 2. Education and training<br>2.1 Professional experiences | 2 |
| 3. Personal skills and competences | 3 |
| 4. Scientific activity<br>4.1 Clinical trial and registry<br>4.2 Oral presentation at congress<br>4.3 Abstract and poster presentation at congress<br>4.4 Scientific Website articles/contributions<br>4.5 Awards and Grants<br>4.6 Organisational responsibilities<br>4.7 Editor Roles and Responsibilities for peer-reviewed academic journal<br>4.8 Journal Reviewer Experiences<br>4.9 Tutorship activities | 4 - 13 |
| 5. Publications<br>5.1 Book chapters | 14 - 20 |
| 6. Varia<br>6.1 Memberships | 20-21 |

## 1. Personal Data

Name: Arturo Cesaro

Date of birth: 10-Jul-1988, Naples, Italy

Nationality: Italian

[redacted]

**Present Position**
*Assistant Professor* of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy
*Cardiologist* at Division of Cardiology – AORN S. Anna e S. Sebastiano – Caserta, Italy

## 2. Education and training

| | |
|---|---|
| 10/2021-ongoing | Research Doctoral Programme in Translational Medicine at University of Campania "L. Vanvitelli", Naples. |
| 31/10/19 | Specialization degree in Cardiology (Cardiovascular disease) at University of Campania "L. Vanvitelli", vote 50/50 cum laude |
| 03/19-02/2020 | Advanced Course *"Statistical Methodology in Biomedical Research and Practice"* at University of Rome "La Sapienza", Italy |
| 1/09/18-1/3/19 | Interventional Cardiology Fellow under the mentorship of Dr. Eduardo Pinar Bermudez, Division of Interventional Cardiology, Hospital Clínico Universitario "Virgen de la Arrixaca", Servicio de Cardiología, Sección de Hemodinámica. Ctra. Madrid-Cartagena, s/n, 30120 El Palmar, Murcia (Spain) |

2015- 2019 Resident in Cardiology under the mentorship of Prof. Paolo Calabrò, Division of Cardiology, Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy. A.O.R.N. “Sant’Anna e San Sebastiano” Caserta (CE), Italy

2014 License to practice Medicine and Surgery - Medical Licence number NA34654. Council of Naples (Ordine dei Medici Chirurghi ed Odontoiatri della provincia di Napoli), Naples (Italy)

2008-2014 Medicine-surgery degree, vote 110/110 cum laude. University of Naples "Federico II", Naples (Italy)

## 2.1 Professional experiences

02/21-ongoing Cardiologist at S. Anna e S. Sebastiano Hospital – Caserta, Italy. Clinical activity focused on Cardiovascular Prevention and Rehabilitation.

10/20-ongoing Assistant Professor of Cardiology, Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Caserta, Italy

1/09/18-1/3/19 Training period of 6 months in the Interventional Cardiology Department at the University Clinical Hospital "Virgen de la Arrixaca" in Murcia – Spain, where I practiced more than 520 diagnostic left cardiac catheterization procedures and 145 coronary angioplasty procedures, most of them as first operator. In addition, I have used techniques for functional evaluation of coronary stenosis (FFR, iFR), intracoronary imaging (IVUS, OCT) and have been involved as a second operator in numerous transcatheter aortic valve replacement (TAVR) procedures.

# 3. Personal skills and competences

2014 BASIC LIFE SUPPORT DEFIBRILLATION (BLSD) - Italian Resuscitation Council (IRC). License number 033711

2017 ADVANCED CARDIOVASCULAR LIFE SUPPORT (ACLS) – American Heart Association

Computer skills: Windows (Word, Excel, PowerPoint, Adobe Acrobat), R, Rstudio, SPSS, Mendeley, EndNote, Internet (Google, PubMed, MEDLINE, Scopus, EMBASE, Web of Science)

Mother tongue(s): Italian

Other language(s):

| | UNDERSTANDING | | SPEAKING | | WRITING |
|---|---|---|---|---|---|
| | Listening | Reading | Spoken interaction | Spoken production | |
| English | B1 | B2 | B1 | B1 | B1 |
| Spanish | B2 | B2 | B2 | B1 | B1 |

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user Common European Framework of Reference for Languages

## 4. Scientific activity

Main fields of research: atherosclerosis, interventional cardiology, myocardial infarction, familial hypercholesterolemia, PCSK9 inhibitors, clinical trials, thrombosis, quantitative flow ratio, coronary angioplasty, OCT, IVUS, FFR, QFR.

Dr. Cesaro does research in cardiology with a focus on the management of patients with acute and chronic coronary syndrome undergoing percutaneous coronary intervention. He has a specific interest in lipid lowering therapies and anti-thrombotic pharmacotherapies and interest in coronary imaging and functional assessment of coronary disease as well as in treatment strategies aiming at reducing cardiovascular risk. Another research line is genetic dyslipidemias with particular interest to the hypercholesterolemia (HeFH and HoFH) and new therapeutic strategies in order to reduce cardiovascular burden in this patient setting.

### 4.1 Clinical trial and registry:

Clinical investigator for the following trials at Division of Cardiology, Department of Medical Translational Sciences, University of Campania “L.Vanvitelli” Naples - Italy, under the supervision of Prof. Paolo Calabrò, MD, PhD:

2015-2016 Protocol 16244 - Finerenone (BAY94-8862): Efficacy and safety of Finenerone in subjects with type 2 Diabetes Mellitus and Diabetic Kidney disease (FIDELIODKD - 16244).

2015-2016 Protocol 17530 - Finerenone (BAY94-8862): Efficacy and safety of Finenerone in subjects with type 2 Diabetes Mellitus and the clinical Diagnosis of Diabetic Kidney disease (FIGARO - DKD - 17530).

2016-2019 VOYAGER PAD Study: BAY 59-7939/174454 - An International, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.

2016-2020 PARADISE-MI: Protocol LCZ696G2301. Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction. A multi-center, randomized, double-blind,

| | |
|---|---|
| | active-controlled, parallel- group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in patients with left ventricular dysfunction following an acute myocardial infarction. |
| 2016 | POSTER: Prevalence Of familial hypercoleSTerolaemia (FH) in Italian Patients with coronary artERy disease (Numero di Protocollo K18). Fondazione SISA (Società Italiana per lo studio dell'Arteriosclerosi) - Fondazione per il Tuo cuore HCF onlus. |
| 2016 | PACSI: Post Acute Coronary Syndrome Italian Study |
| 2016-2020 | DAL-GENE Trial: Protocol n. DAL-301. A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS). |
| 2017 | EYESHOT Post-MI: (EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTaly) Post-MI Registry. Fondazione per il Tuo cuore HCF onlus. |
| 2017-2020 | Protocollo Amgen 20130296 – registro osservazionale Repatha (evolocumab) |
| 2018-ongoing | OMERO: Observational, prospective, multicentre study on long-term effectiveness and tolerability of alirocumab in the real life clinical practice in Italy |
| 2018-2021 | Protocol EDO-SP-01-2015: A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation (NCT03489395) |
| 2019-ongoing | Adhere registry: Adherence to pHarmacological thErapy in Real world with acute coronary syndromes |
| 2019-ongoing | PERSEO Registry: PERcutaneouS coronary intErventions in patients treated with Oral anticoagulant therapy |
| 2019-2021 | MASTER DAPT: Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen (NCT03023020) |
| 2019-2020 | Beneficio clinico netto dei farmaci anticoagulanti orali non antagonisti della vitamina K rispetto ai farmaci inibitori della vitamina K in pazienti con fibrillazione atriale ed insufficienza renale severa: studio osservazionale, multicentrico, di mondo reale. |
| 2019-ongoing | AEGIS-II: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome |

2019-ongoing MONET study: Maintenance Of aNtiplatElet Therapy in patients with coronary stenting undergoing surgery

2019-ongoing ENVISAGE-TAVI AF: Edoxaban Versus Standard Of Care And Their Effects On Clinical Outcomes In Patients Having Undergone Transcatheter Aortic Valve Implantation – In Atrial Fibrillation Edoxaban (Du-176b-C-U4001)

2019-ongoing ADHERE: ADherence to pHarmacological therapy in REal-world patients with acute coronary syndromes (the ADHERE registry)

2019-ongoing ESCALATE study: Efficacy and Safety of Coronary Amphilimus eLuting stent in diAbeTic patiEnts:a cross-sectional multicentre consecutive study.

2019- ongoing PARTHENOPE trial: Randomized 2x2 factorial trial comparing the Cre8 amphilimus-eluting stent vs. the synergy everolimus-eluting stent in all-comers patients undergoing percutaneous coronary intervention and a personalized vs. standard duration of dual antiplatelet therapy.

2020- ongoing Zenon study: A Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Formulation of Zenon (Ezetimibe/Rosuvastatin Fixed Dose Combination) in Patients With Primary Hypercholesterolemia, Not Adequately Controlled on Statin Therapy

2020- ongoing SANTORINI study: Registro sul Trattamento dell'Ipercolesterolemia Primaria per la Prevenzione di Eventi Cardiovascolari in Europa

2020- ongoing ARCANGELO (itAlian pRospective study on CANGrELOr). A multicentre observational, prospective cohort study including patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. transitioning to either clopidogrel, prasugrel or ticagrelor per os.

2022-ongoing A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) – Protocol n° 20210057

**Committee Member in Clinical Trials**

2020 TAPER-S (EudraCT No. 2016-004746-28), Committee Member for data and safety monitoring

## 4.2 Oral presentation at congress

2017 Ipercolesterolemia Familiare Omozigote: una malattia rara curabile: caso clinico introduttivo. 9th november 2017 - Cooperativa Co.me.gen. Naples (Italy)

2017 Effetti metabolici e vascolari degli inibitori di PCSK9 in una popolazione a rischio cardiovascolare elevato e molto elevato. 78° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2018 Il paziente a rischio cardiovascolare intermedio. “Strategia terapeutica ottimale per il paziente ipercolesterolemico a basso-medio e alto rischio cardiovascolare…un approccio personalizzato” - Caserta, 26th May 2018 AORN Sant’Anna e San Sebastiano, Caserta (Italy)

2018 Cardiopatia ischemica cronica: approccio clinico e certezze terapeutiche. Update in Cardiology – 7th June 2018, Nola Cuore. Nola (NA, Italy).

2018 Evolocumab: un nuovo paradigma per il paziente ad alto rischio. “Metti a fuoco il paziente a rischio 3.0” 12th June 2018, Caserta (Italy).

2018 UPDATE nel Trattamento delle Dislipidemie: Caso clinico introduttivo. VI Scientific Symposium - Update in Cardiology. December 4th, 2018, Caserta (Italy).

2019 PROGRESS:"Investigation about the correct apPROach for a GREat and Successfull Post-SCA management". CVRM External Research Summit. 7-8th February 2019 – Madrid (Spain)

2019 Il rischio ischemico supera quello emorragico. Cardionefrologia 2019 – 12-14$^{th}$ March – Roma (Italy)

2019 Durata ottimale della DAPT dopo stenting coronarico…Nel paziente con FA – XVII Congresso Nazionale SICOA – 4-7th April 2019 – Naples (Italy)

2019 PCSK9 inibitori: una terapia per tutti o per pochi? – Scilla Cuore 2019 – 28-29-30th April – 1st May – Scilla (RC) (Italy)

2019 Riflessioni sul RE-DUALPCI e sul PIONEER AF-PC – XVI congresso regionale ANMCO – 10-11th May 2019 – Pozzuoli (Italy)

2019 The role of peripheral intervention to facilitate success in valvular and coronary intervention – 20$^{th}$ June 2019 – Naples (Italy)

2019 Come raggiungere gli obiettivi raccomandati di LDL colesterolo. XIII Update Cardiovascolare 2019. 11th October 2019 – Naples (Italy)

2019 Caso Clinico: paziente dislipidemico - Ipertensione arteriosa, dislipidemia e diabete mellito: l’importanza dell’aderenza terapeutica. Gestione continuità Ospedale-Territorio – 18-19th October 2019 – Sorrento (Italy)

2019 Come associare la giusta dose al giusto paziente: problemi non risolti della terapia anticoagulante nella fibrillazione atriale- CBM CARDIO 2019 – 25-26 Ottobre 2019, Campus Biomedico – Roma (Italia)

| | |
|---|---|
| 2019 | Caso Clinico: Accesso Vascolare - II Corso Hands On nel laboratorio di emodinamica - 18 Novembre 2019 - Caserta (Italia). |
| 2019 | L'utilizzo di Ticagrelor 60 mg: trial clinici e mondo reale - VII Simposio Scientifico - Update in Cardiologia - 19-20 Novembre 2019 - Caserta (Italia). |
| 2019 | La terapia di associazione: in quali pazienti? – 33° Congresso Nazionale S.I.S.A. – 26-26 Novembre 2019, Roma (Italia) |
| 2020 | PCSK9 inhibitors: indications and advantages in cancer patients - III International Workshop on Cardioncology - VI Congresso Nazionale in Cardioncologia – 31 Gennaio – 1 Febbraio 2020 – Napoli (Italia) |
| 2020 | Twitter Case: FA e SCA - NAO…It's Twitter Time – 20 Febbraio 2020 – Napoli (Italia) |
| 2021 | I colori dell'aderenza – 14 Aprile 2021 – Webinar |
| 2021 | Linee Guida ESC 2019 per la gestione e il trattamento delle dislipidemie: 10 key point - "Combattere il Colesterolo per ridurre il rischio cardiovascolare: vecchie e nuove strategie di associazione farmacologica" - webinar 10 giugno 2021 |
| 2021 | Strategie terapeutiche di associazione statine/ezetimibe: efficacia nel raggiungimento dei target e riduzione degli eventi cardiovascolari - "Combattere il Colesterolo per ridurre il rischio cardiovascolare: vecchie e nuove strategie di associazione farmacologica" - webinar 10 giugno 2021 |
| 2021 | Paziente con FA ed anziano - NAOlab_FA 17 Giugno 2021 FAD SINCRONO – Webinar live |
| 2021 | Paziente con malattia Multivasale CAD-PAD. PROTEZIONE ANTITROMBOTICA NEL PAZIENTE AD ALTO RISCHIO CARDIO CEREBRO VASCOLARE – 21 Settembre 2021 – FAD |
| 2021 | Triplice terapia con acido bempedoico e statina/ezetimibe per il rischio evitabile nel paziente con malattia aterosclerotica cardiovascolare – 1-2 Ottobre, Campus Cuore – Napoli |
| 2021 | Simposio "COVID-19: impatto clinico, organizzativo e di prospettiva della Cardiologia Riabilitativa e Preventiva" - impatto clinico -ITACARE-P (ITalian Alliance for Cardiovascular REhabilitation and Prevention) – 26 Novembre 2021, Milano |
| 2021 | NUOVI E VECCHI ATTORI NEL TRATTAMENTO DELLO SCOMPENSO CARDIACO - Paziente con cardiomiopatia dilatativa primitiva e diabete mellito di tipo 2 – 82esimo Congresso della Società Italiana di Cardiologia, 9-12 Dicembre, Roma. |
| 2022 | PAZIENTI SEMPRE PIÙ COMPLESSI ED IN POLITERAPIA: È GIUNTO IL MOMENTO DELLA POLYPILL. "COMB IN ACTION" 18 - 19 marzo 2022,Sorrento |

2022 SIMPOSIO - LLGG ESC UN ANNO DOPO: VALUTAZIONE CRITICA – 53°Congresso Nazionale ANMCO, 19-21 maggio, Rimini.

2022 GESTIONE INTEGRATA DI SCENARI CLINICI COMPLESSI: NUOVE OPZIONI TERAPEUTICHE PER FIBRILLAZIONE ATRIALE E DISLIPIDEMIA 23 MAGGIO 2022 - GRAND HOTEL VANVITELLI CASERTA

2022 UP-Date sui PCSK9-I: trattamento precoce, nuovi target, criteri di eleggibilità - Napoli 17-18/6/2022

2022 "Homozygous familial hypercholesterolemia: what we have learned in recent years" at the XXXIV Congreso de la Sociedad Española de Arteriosclerosis ("SEA") Congress 2022 on June 9th, 2022. Madrid, Spain from 8 to 10 June 2022

2022 Inclisiran: quando e in quale paziente utilizzarlo? XX CONGRESSO NAZIONALE SICOA, 23-25 giugno 2022, Napoli

## 4.3 Abstract and poster presentation at congress

2016 **A. Cesaro**, F. Natale, S. Sperlongano, I. Pariggiano, F. Gragnano, V.Diana, M. Crisci, F. Fimiani, R. Calabrò, M.G. Russo, P. Calabrò."Ipercolesterolemia familiare e nuove strategie terapeutiche: esperienza preliminare con inibitori di PCSK9. 77° Congresso Nazionale della Società Italiana di Cardiologia (SIC) – 16-19th December 2016, Rome, Italy.

2016 S. Sperlongano, C. Garaffa, M. Laringe, E. Garaffa, I. Pariggiano, **A.Cesaro**, F. Fimiani, F. Natale, R. Calabrò, M. G. Russo, G. Piccinocchi, P. Calabrò. "Impiego del Dutch Score e screening a cascata per l'identificazione dei pazienti affetti da ipercolesterolemia familiare omozigote e trattamento con lomitapide". 77° Congresso Nazionale della Società Italiana di Cardiologia (SIC) - 16-19th December 2016, Rome, Italy.

2017 Gragnano F, Carbone A, Crisci M, Cappelli Bigazzi M, Bianchi R, Tartaglione D, Sperlongano S, Natale F, Fimiani F, Concilio C, **Cesaro A**, Pariggiano I, Diana V, Limongelli G, Russo MG, Golia E, and Calabrò P. Management of iron deficiency and anemia in patients undergoing TAVR: a case report. 5th International Multidisciplinary Course on Iron Anemia. 2017, 31th March, 1st April. Florence, Italy.

2017 Gragnano F, Concilio C, **Cesaro A**, Crisci M, Sperlongano S, Fimiani F, Natale F, Pezzullo E, Calabrò R, Russo MG, Calabrò P. Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy. SPRING meeting Giovani Ricercatori SIIA, SIMI e SISA. Novità nello studio dell'aterosclerosi e delle sue complicanze. 2017, 7th-8th April. Rome, Italy.

2017 Gragnano F, Concilio C, **Cesaro A**, Crisci M, Sperlongano S, Fimiani F, Natale F, Pezzullo E, Calabrò R, Russo MG, Calabrò P. (P1513)Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy. European Society of Cardiology (ESC) Congress. 2017, 27th August. Barcelona, Spain. European Heart Journal, Volume 38, Issue suppl_1, 1 August 2017, ehx502.P1513, https://doi.org/10.1093/eurheartj/ehx502.P1513.

2017 R De Vecchis; C Ariano; **A Cesaro**; A Giasi; C Cioppa. Ranolazine alone or as an add-on to amiodarone for both prevention and cardioversion of atrial fibrillation in patients with or without chronic heart failure: a metaanalysis of the literature. Abstracts of the Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, Paris, France, 29 April – 2 May 2017

2017 Gragnano F, Bianchi R, Cappelli Bigazzi M, Diana V, Crisci M, Tartaglione D, Natale F, Fimiani F, Concilio C, **Cesaro A**, Pariggiano I, Limongelli G, Russo M, Golia E, Calabrò P. (P151) Tips and tricks in post-TAVR percutaneous coronary intervention: review of the literature and single-center series. National Congress Italian Society of Interventional Cardiology (GISE) (Milan, October 2017).

2017 Pirolli R, Bianchi R, Crisci M, Tartaglione D, Diana V, Gragnano F, **Cesaro A**, Golia E, Cappelli Bigazzi M, Russo M, Calabrò P. Follow-up a lungo termine dell'utilizzo di amphilimus sirolimus eluting stent in pazienti con SCA e confronto con popolazione diabetica. 78° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2017 Sperlongano S, Gragnano F, Natale F, Golia E, Concilio C, **Cesaro A**, Diana V, Crisci M, Limongelli G, Russo M, Calabrò P. Utilizzo di lomitapide nei pazienti con ipercolesterolemia familiare omozigote: la nostra esperienza. 78° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2017 Crisci M, Vergara A, Manzi L, Bianchi R, Cappelli Bigazzi M, Tartaglione D, Gragnano F, **Cesaro A**, Calabrò R, Russo M, Calabrò P. Sicurezza dell'utilizzo degli inibitori GPIIb/IIIa nei pazienti con infarto del miocardio con sopraslivellamento persistente del tratto st in età giovanile. 78° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2017 Crisci M, Manzi L, Vergara A, Gragnano F, Golia E, Bianchi R, **Cesaro A**, Fimiani F, Diana V, Calabrò R, Russo M, Calabrò P. Esperienza “real-life” dei pazienti affetti da sindrome coronarica acuta e fibrillazione atriale in triplice terapia con dabigatran, ASA e clopidogrel. 78° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2017 Crisci M, Peluso A, Lauretta D, Dinardo G, Gragnano F, Golia E, Diana V, **Cesaro A**, Bianchi R, Russo M, Calabrò P. Compliance ed aderenza alla doppia terapia antiaggregante con ticagrelor e aspirina nei pazienti con sindrome coronarica acuta: progress trial78° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2017 F. Gragnano, C. Concilio, **A. Cesaro**, M. Crisci, S. Sperlongano, F. Fimiani, F. Natale, E. Pezzullo, R. Calabrò, M. Russo, P. Calabrò. Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real world setting: results from a single center experience and comparision with statin therapy. 78° Congresso Nazionale della Società Italiana di Cardiologia (SIC) - 15-18th December 2017, Roma IT.

2017 **Cesaro A**, Concilio C, Natale F, Gragnano F, Sperlongano S, Fimiani F, Crisci M, Diana V, Bianchi R, Calabrò R, Russo G, Limongelli G, Golia E, Calabrò P. Effetti metabolici e vascolari degli inibitori di pcsk9 in una popolazione a rischio cardiovascolare elevato e molto elevato. 78° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2018 **Arturo Cesaro**, Felice Gragnano, Fabio Fimiani, Francesco Natale, Renatomaria Bianchi, Mario Crisci, Antonio Shatri, Giuseppe Limongelli, Raffaele Calabrò, Paolo Calabrò. Lipoprotein(a) screening in patients with premature myocardial infarction: clinical role and impact on decision-making. Spring Meeting Gruppi Giovani SIIA, SIMI, SISA - 6-7th April 2018, Rimini (Italy)

2018 Gragnano F, Fimiani F, Natale F, **Cesaro A**, Bianchi R, Crisci M, Shatri A, Limongelli G, Calabrò R, Calabrò P. Lipoprotein(a) screening in patients with premature myocardial infarction: clinical role and impact on decision-making. Awarded for “Young Investigator Fellowship”. 86th European Atherosclerosis Society (EAS) Congress, May 6th, Lisbon. Published on Atherosclerosis (August 2018, 275). doi: 10.1016/j.atherolscerosis.2018.06.484.

2018 Fimiani F, **Cesaro A**, Gragnano F, Ranieri A, Gentile L, Cesarano M, Falato S, D’Alicandro G, Pastore L, Lombardo B, Scudiero O, Calabrò P. Biochemical role of lipoprotein screening in patients with premature miocardial infarction and in elite athletes. 50th Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC). October 2018, Naples (Italy).

2018 F. Gragnano, F. Fimiani, M. Di Maio, F. Natale, **A. Cesaro**, M. Crisci, R. Bianchi, I. Pariggiano, E. Moscarella, A. Shatri, V. Gallinoro, F. Terracciano, R. Vitale, F. Borrelli, F. Nappi, M. Papa, A. Agresti, F. Cesaro, M. Di Stasio, A. Ruggiero, M. Soletti, D. Soviero, G. Limongelli, P. Calabro´. Lipoprotein(a) levels in patients with premature coronary artery disease undergoing percutaneous coronary intervention (PCI): impact on recurrent cardiovascular events and clinical management.

79° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2018 **A. Cesaro**, F. Gragnano, F. Fimiani, A. Scarda, E. Moscarella, C. Annoiato, I. Pariggiano, V. Diana, V. Carfora, M. Conte, S. Falato, M. Cesarano, D. Di Maio, F. Agricola, F. Massaro, I. Maddaluno, V. Allocca, D. Lisi, E. Sgueglia, M. Mensorio, A. Matano, P. Calabro´. Impatto sulla qualità della vita del trattamento con inibitori di PCSK9 in pazienti a rischio cardiovascolare elevato e molto elevato. 79° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2018 I. Pariggiano, **A. Cesaro**, F. Gragnano, C. Mignano, N. Di Meo, E. Sgueglia, D. Lisi, M. Mensorio, A. Matano, J. Barrabes, P. Calabrò. L'ampiezza di distribuzione eritrocitaria al ricovero non predice il rimodellamento ventricolare in pazienti con un infarto miocardico anteriore. 79° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2019 **A. Cesaro**, F. Gragnano, F. Fimiani, E. Moscarella, I. Pariggiano, V. Diana, V. Carfora, M. Conte, S. Falato, M. Cesarano, D. Di Maio, P. Calabrò. Quality Of Life Improvement in high and very high cardiovascular risk patients treated with PCSK9 inhibitors. Abstract number: EAS19-1062 87th European Atherosclerosis Society Congress (EAS 2019) Maastricht, The Netherlands| 26-29, May 2019.

2019 **A. Cesaro,** F. Fimiani, F. Gragnano, E. Moscarella, V. Diana, I. Pariggiano, C. Concilio, A. Mattera Iacono, F. Villani, A. Esposito, D. Di Maio, G. Parente, D. Lisi, E. Sgueglia, G. Limongelli, P. Calabrò. Biochemical role of lipoprotein screening in patients with premature myocardial infarction and in elite athletes. 80° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2019 P. Calabrò, F. Gragnano, E. Moscarella, **A. Cesaro**, F. Fimiani, A.R. Vitale, C.P. Pafundi, G. Patti, I. Cavallari, E. Antonucci, L. Lombardi, G. Parente, R. D'Antonio, M. Conte, P. Cirillo, P. Pignatelli, G. Palareti, F. Sasso,V. Pengo, P. Gresele, R. Marcucci Impact of high bleeding risk (HBR) features on antithrombotic management and long-term outcomes in patients with acute coronary syndrome: data from the multicenter START-antiplatelet registry. 80° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2019 P. Calabrò, E. Moscarella, F. Gragnano, **A. Cesaro**, C.P. Pafundi, M. Cesarano, G. Patti, D. Di Maio, M. Conte, I. Cavallari, E. Antonucci, P. Cirillo, P. Pignatelli, G. Palareti, C.F. Sasso, V. Pengo, P. Gresele, R. Marcucci. Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes: from the START antiplatelet registry. 80° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2019 **A. Cesaro**, F. Gragnano, F. Fimiani, E. Moscarella, V. Diana, I. Pariggiano, C. Concilio, A. Mattera Iacono, A. Schiavo, V. Coscia, E.

Monda, G. Limongelli, P. Calabrò. Quality of life assessment in patients treated with PCSK9 inhibitors. 80° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

2019 **A. Cesaro**, F. Gragnano, E. Moscarella, F. Fimiani, S. Falato, V. Carfora, A. De Michele, D. Rubino, V. Diana, I. Pariggiano, C. Concilio, A. Mattera Iacono, M. Mensorio, A. Matano, G. Limongelli, P. Calabrò Ticagrelor 60 mg in the real-world setting: safety and effectiveness. 80° Congresso Nazionale della Società Italiana di Cardiologia (SIC), Rome, (Italy).

## 4.4 Collaborations/contributions for scientific websites

2018-in corso Editorial Board for CARDIOTALK – La cardiologia in presa diretta. https://www.cardiotalk.it/redazioni

2019 **Cesaro A.** La terapia con Evolocumab nei pazienti con arteriopatia degli arti inferiori. (SISA Update, Società Italiana per lo Studio dell'Aterosclerosi). http://www.sisa.it/index.php?class=Comp&className=Content&op=Show&param=cid,1200,preview,0

## 4.5 Awards and Grants

2019 Grant Winner for EAPCI-PCR Fellows Course 2019 - EuroPCR 2019 - 21-24 MAY 2019, Palais des Congrès, Paris, France.

2021 Best Abstract Award – 82nd Congress of Italian Society of Cardiology – 9-12 December 2021, Rome, Italy.

## 4.6 Organisational responsibilities

**Congress Programme Committee**
Member of the Congress Programme Committee (CPC) in the following scientific events and congresses:

2018 VI Scientific Symposium - Update in Cardiology. December 3rd and 4th, 2018, Caserta - Italy.

2019 VII Scientific Symposium - Update in Cardiology. November 18th- 19th and 20th, 2019, Caserta - Italy.

2020 VIII Scientific Symposium - CardioUpdate. October 2020, Caserta - Italy.

2021 IX Scientific Symposium - CardioUpdate. November 2021, Caserta - Italy.

## 4.7 Editor Roles and Responsibilities for peer-reviewed academic journal

2022 **Section Editor** for Current Cardiology Reviews

2021 **Reviewer Editor** for *Frontiers in Cardiovascular Disease*
6.050 2-year Impact Factor

2021 **Reviewer Editor** for *Frontiers in Endocrinology*
5.555 2-year Impact Factor

2021 **Academic Editor** for *PloS One*
3.240 2-year Impact Factor

2021 **Editorial Board Member** for Healthcare – MDPI - ISSN 2227-9032
1.916 - 2-year Impact Factor

2020 **Associate Editor** for *BMC Cardiovascular Disorders* – Springer Nature - ISSN: 1471-2261
2.078 - 2-year Impact Factor
2.16 - 5-year Impact Factor

2020 **Topic Editor** for *Cardiogenetics* – MDPI - ISSN 2035-8148

## 4.8 Journal Reviewer Experiences

Reviewer for peer-reviewed Journals (115 reviews certified on Publons)

Peer-reviewer for:

- European Journal of Preventive Cardiology
- Nutrition, Metabolism & Cardiovascular Diseases
- Journal of Cardiovascular Medicine
- Journal of Clinical Medicine
- Nutrients
- International Journal of Public Health and Environmental Research
- Plos One
- Journal of Personalized Medicine
- BMC Cardiovascular Disorders
- Clinical Medicine Insights: Case Reports
- Expert Review of Cardiovascular Therapy
- Biomedicines
- Clinical and Applied Thrombosis/Hemostasis
- Platelets
- Pathogens
- International Journal of Cardiology

## 4.9 Tutorship activities

Since 2015, tutoring of more than 20 students for data collection and thesis writing at the Chair of Cardiology of the University of Campania "L. Vanvitelli"

## 5. Publications

ORCID ID: https://orcid.org/0000-0003-4435-1235

| | List of Publications |
|---|---|
| 1. | Gragnano F, Crisci M, Bigazzi MC, Bianchi R, Sperlongano S, Natale F, Fimiani F, Concilio C, **Cesaro A,** Pariggiano I, Diana V, Limongelli G, Cirillo P, Russo M, Golia E, Calabrò P. *Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement.* Angiology. 2017 Jan 1:3319717708070. doi: 10.1177/0003319717708070. |
| 2. | De Vecchis R, Noutsias M, Ariano C, **Cesaro A,** Cioppa C, Giasi A, Maurea N. *Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?* J Clin Med Res. 2017 Apr;9(4):266-272. doi: 10.14740/jocmr2933w. Epub 2017 Feb 21. |
| 3. | De Vecchis R, **Cesaro A,** Ariano C. *Differential effects of phosphodiesterase-5 inhibition in chronic cardiac decompensation, depending on the type, whether HFREF or HFpEF, of heart failure: a meta-analysis.* Minerva Cardioangiol. 2017 Apr 10. doi: 10.23736/S0026-4725.17.04382-1. |
| 4. | De Vecchis R, **Cesaro A,** Ariano C, Giasi A, Cioppa C. *Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.* J Clin Med Res. 2017 Jun;9(6):488-498. doi: 10.14740/jocmr3008w. |
| 5. | Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M, Fimiani F, Pariggiano I, Diana V, Carbone A, **Cesaro A**, Concilio C, Limongelli G, Russo M, Calabrò P. *The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.* Mediators Inflamm. 2017;2017:5620314. doi: 10.1155/2017/5620314. Epub 2017 May 28. |
| 6. | Gragnano F, Natale F, Concilio C, Fimiani F, **Cesaro A,** Sperlongano S, Crisci M, Limongelli G, Calabrò R, Russo M, Golia E, Calabrò P. *Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.* J Cardiovasc Med (Hagerstown). 2017 Dec 14. doi: 10.2459/JCM.0000000000000611. |

| | |
|---|---|
| 7. | Sperlongano S, Gragnano F, Natale F, D'Erasmo L, Concilio C, **Cesaro A,** Golia E, Crisci M, Sperlongano R, Fimiani F, Russo M, Arca M, Limongelli G, Calabrò P. *Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.* J Cardiovasc Med (Hagerstown). 2018 Mar;19(3):83-90. doi: 10.2459/JCM.0000000000000620 |
| 8. | Calabrò P, Gragnano F, **Cesaro A.** *Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)"* Circulation. 2018 Jul 10;138(2):218-219. doi: 10.1161/CIRCULATIONAHA.117.033137. |
| 9. | **Cesaro A,** Gragnano F, Di Girolamo D, Moscarella E, Diana V, Pariggiano I, Alfieri A, Perrotta R, Golino P, Cesaro F, Mercone G, Campo G, Calabrò P. *Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?* Expert Rev Cardiovasc Ther. 2018 Dec;16(12):951-962. doi: 10.1080/14779072.2018.1540303. |
| 10. | Lombardo B, Izzo V, Terracciano D, Ranieri A, Mazzaccara C, Fimiani F, **Cesaro A,** Gentile L, Leggiero E, Pero R, Izzo B, D'Alicandro AC, Ercolini D, D'Alicandro G, Frisso G, Pastore L, Calabrò P, Scudiero O. *Laboratory medicine: health evaluation in elite athletes.* Clin Chem Lab Med. 2019 Mar 5. doi: 10.1515/cclm-2018-1107. |
| 11. | **Cesaro A,** Gragnano F, Fimiani F, Moscarella E, Diana V, Pariggiano I, Concilio C, Natale F, Limongelli G, Bossone E, Calabrò P. *Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk.* Eur J Prev Cardiol. 2019 Mar 26:2047487319839179. doi: 10.1177/2047487319839179. [Epub ahead of print] |
| 12. | Gragnano F, Fimiani F, Di Maio M, **Cesaro A,** Limongelli G, Cattano D, Calabrò P. *Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease.* Intern Emerg Med. 2019 Jun;14(4):621-625. doi: 10.1007/s11739-019-02082-8. Epub 2019 Mar 30. |
| 13. | Crisci M, Gragnano F, Di Maio M, Diana V, Moscarella E, Pariggiano I, Di Maio D, Concilio C, Taglialatela V, Fimiani F, **Cesaro A,** Cirillo PL, Calabrò P. *Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial.* Curr Vasc Pharmacol. 2019 May 24. doi: 10.2174/1570161117666190524123225. [Epub ahead of print] |
| 14. | Calabrò P, Gragnano F, **Cesaro A,** Pariggiano I, Patti G, Cavallari I, Parato VM, Renda G, De Caterina R; a nome del Gruppo di Studio sulla Trombosi della Società Italiana di Cardiologia. *Atrial and left atrial appendage thrombosis in patients with* |

| | |
|---|---|
| | *atrial fibrillation: from pathophysiology to treatment.* G Ital Cardiol (Rome). 2019 Jun;20(6):374-383. doi: 10.1714/3165.31471. |
| 15. | **Cesaro A,** Moscarella E, Gragnano F, Perrotta R, Diana V, Pariggiano I, Concilio C, Alfieri A, Cesaro F, Mercone G, Falato S, Esposito A, Di Girolamo D, Limongelli G, Calabrò P. *Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events.* Expert Rev Cardiovasc Ther. 2019 Jun;17(6):435-447. doi: 10.1080/14779072.2019.1627873. |
| 16. | Gragnano F, Spedicato V, Frigoli E, Gargiulo G, Di Maio D, Fimiani F, Fioretti V, Annoiato C, Cimmino M, Esposito F, Chianese S, Scalise M, Fimiani L, Franzese M, Monda E, Schiavo A, **Cesaro A,** De Michele A, Scalise R, Caracciolo A, Andò G, Stabile E, Windecker S, Calabrò P, Valgimigli M. *ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial.* J Electrocardiol. 2019 Aug 28;57:44-54. doi: 10.1016/j.jelectrocard.2019.08.045. |
| 17. | Calabrò P, Moscarella E, Gragnano F**, Cesaro A,** Pafundi PC, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Sasso FC, Pengo V, Gresele P, Marcucci R; START-ANTIPLATELET. *Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry).* Am J Cardiol. 2019 Sep 6. pii: S0002-9149(19)30996-8. doi: 10.1016/j.amjcard.2019.08.030 |
| 18. | Esposito A, Monda E, Gragnano F, Simone F, **Cesaro A,** Natale F, Concilio C, Moscarella E, Caiazza M, Pazzanese V, Verrengia M, Valente F, Masarone D, Pelliccia F, Bossone E, Calabro' P, Pacileo G, Limongelli G. *Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism*. Eur J Prev Cardiol. 2019 Nov 12:2047487319888596. |
| 19. | Scudiero O, Pero R, Ranieri A, Terracciano D, Fimiani F, **Cesaro A,** Gentile L, Leggiero E, Laneri S, Moscarella E, Mazzaccara C, Frisso G, D'Alicandro G, Limongelli G, Pastore L, Calabrò P, Lombardo B. *Childhood obesity: an overview of laboratory medicine, exercise and microbiome*. Clin Chem Lab Med. 2019 Dec 10. pii: /j/cclm.ahead-of-print/cclm-2019-0789/cclm-2019-0789.xml. |
| 20. | **Cesaro A**, Bianconi V, Gragnano F, Moscarella E, Fimiani F, Monda E, Scudiero O, Limongelli G, Pirro M, Calabrò P. *Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition*. Biofactors. 2020 Jan 30. doi: 10.1002/biof.1619. [Epub ahead of print] |

| | |
|---|---|
| 21. | Calabrò P**, Cesaro A.** *Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach*. Eur J Prev Cardiol. 2020 Apr 20:2047487320919235. doi: 10.1177/2047487320919235. |
| 22. | Gragnano F, Moscarella E, Calabrò P, **Cesaro A**, Pafundi PC, Ielasi A, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Pelliccia F, Gaudio C, Sasso FC, Pengo V, Gresele P, Marcucci R; START-ANTIPLATELET Collaborators. *Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.* Intern Emerg Med. 2020 Jun 15. doi: 10.1007/s11739-020-02404-1. |
| 23. | Brancaccio M, Mennitti C, Laneri S, Franco A, De Biasi MG, **Cesaro A**, Fimiani F, Moscarella E, Gragnano F, Mazzaccara C, Limongelli G, Frisso G, Lombardo B, Pagliuca C, Colicchio R, Salvatore P, Calabrò P, Pero R, Scudiero O. *Methicillin-Resistant Staphylococcus aureus: Risk for General Infection and Endocarditis Among Athletes.* Antibiotics (Basel). 2020 Jun 18;9(6):E332. doi: 10.3390/antibiotics9060332. |
| 24. | **Cesaro A**, Taglialatela V, Gragnano F, Moscarella E, Fimiani F, Conte M, Barletta V, Monda E, Limongelli G, Severino S, Cirillo P, Calabrò P. *Low-dose Ticagrelor in Patients With High Ischemic Risk and Prior Myocardial Infarction: a Multicenter Prospective Real-World Observational Study.* J Cardiovasc Pharmacol. 2020 Jun 17. doi: 10.1097/FJC.0000000000000856. |
| 25. | Calabrò P, Gragnano F, **Cesaro A**, Marsico F, Pariggiano I, Patti G, Moscarella E, Cavallari I, Sardu C, Parato VM, Renda G, Niccoli G, Marcucci R, De Caterina R; Working Group of Thrombosis and; Working Group of Interventional Cardiology of the Italian Society of Cardiology. *Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence.* Cardiovasc Dis. 2020 Jul 22;S1875-2136(20)30138-8. doi: 10.1016/j.acvd.2020.03.019 |
| 26. | **Cesaro A**, Calabrò P. *Coronary stent thickness: thinner is (always) better for all lesions?* J Cardiovasc Med (Hagerstown). 2020 Jul 27. doi: 10.2459/JCM.0000000000001052. |
| 27. | **Cesaro A**, Bravo IG, Calabrò P, Bermudez EP. *Rheumatic mitral stenosis in a 28-week pregnant woman treated by mitral valvuloplasty guided by low dose of radiation: a case report and brief overview.* Gen Thorac Cardiovasc Surg. 2020 Aug 27. doi: 10.1007/s11748-020-01465-5 |

| | |
|---|---|
| 28. | **Cesaro A**, Schiavo A, Moscarella E, Coletta S, Conte M, Gragnano F, Fimiani F, Monda E, Caiazza M, Limongelli G, D'Erasmo L, Riccio C, Arca M, Calabrò P. *Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies.* J Cardiovasc Med (Hagerstown). 2020 Aug 26. doi: 10.2459/JCM.0000000000001077. |
| 29. | Moscarella E, Gragnano F, **Cesaro A**, Ielasi A, Diana V, Conte M, Schiavo A, Coletta S, Di Maio D, Fimiani F, Calabrò P. *Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease*. Cardiol Clin. 2020 Nov;38(4):575-588. doi: 10.1016/j.ccl.2020.07.003. |
| 30. | Monda E, Frisso G, Rubino M, Caiazza M, Esposito A, Cirillo A, Fusco A, Palmiero G, Mazzaccara C, Pacileo R, Verrillo F, Di Fraia F, Gragnano F, **Cesaro A**, Salvatore F, Russo MG, Calabrò P, Pacileo G, Dellegrottaglie S, Limongelli G. *Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy.* Future Cardiol. 2020 Oct 21. doi: 10.2217/fca-2020-0107. |
| 31. | Brancaccio M, Mennitti C, **Cesaro A**, Fimiani F, Moscarella E, Caiazza M, Gragnano F, Ranieri A, D'Alicandro G, Tinto N, Mazzaccara C, Lombardo B, Pero R, Limongelli G, Frisso G, Calabrò P, Scudiero O. *Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity*. Int J Environ Res Public Health. 2020 Dec 16;17(24):9424. doi: 10.3390/ijerph17249424. |
| 32. | Scudiero O, Lombardo B, Brancaccio M, Mennitti C, **Cesaro A**, Fimiani F, Gentile L, Moscarella E, Amodio F, Ranieri A, Gragnano F, Laneri S, Mazzaccara C, Di Micco P, Caiazza M, D'Alicandro G, Limongelli G, Calabrò P, Pero R, Frisso G. *Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination.* Int J Environ Res Public Health. 2021 Jan 21;18(3):904. doi: 10.3390/ijerph18030904. |
| 33. | Monda E, Fusco A, Della Corte A, Caiazza M, Cirillo A, Gragnano F, Giugliano MP, Citro R, Rubino M, Esposito A, **Cesaro A**, Di Fraia F, Palmiero G, Di Maio M, Monda M, Calabrò P, Frisso G, Nistri S; Bicuspid Aortic Valve Consortium (BAVCon), Bossone E, Body SC, Russo MG, Limongelli G. *Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve.* Pediatr Cardiol. 2021 Jun;42(5):1133-1140. doi: 10.1007/s00246-021-02591-4. |
| 34. | **Cesaro A,** Riccio C, Calabrò P. *Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target.* Monaldi Arch Chest Dis. 2021 May 4;91(2). doi: 10.4081/monaldi.2021.1721. |

| | |
|---|---|
| 35. | Palmiero G, **Cesaro A**, Vetrano E, Pafundi PC, Galiero R, Caturano A, Moscarella E, Gragnano F, Salvatore T, Rinaldi L, Calabrò P, Sasso FC.*Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects*. Int J Mol Sci. 2021 May 30;22(11):5863. doi: 10.3390/ijms22115863. |
| 36. | Marfella R, Paolisso P, Sardu C, Palomba L, D'Onofrio N, **Cesaro A,** Barbieri M, Rizzo MR, Sasso FC, Scisciola L, Turriziani F, Galdiero M, Pignataro D, Minicucci F, Trotta MC, D'Amico M, Mauro C, Calabrò P, Balestrieri ML, Signoriello G, Barbato E, Galdiero M, Paolisso G. *SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction.*<br>Crit Care. 2021 Jun 24;25(1):217. doi: 10.1186/s13054-021-03643-0. |
| 37. | Caturano A, Galiero R, Pafundi PC, **Cesaro A,** Vetrano E, Palmiero G, Rinaldi L, Salvatore T, Marfella R, Sardu C, Moscarella E, Gragnano F, Calabrò P, Sasso FC. Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. Diabetes Res Clin Pract. 2021 Aug;178:108959. doi: 10.1016/j.diabres.2021.108959. |
| 38. | Gragnano F, Cesaro A, Pelliccia F, Calabrò P. Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter. Int J Cardiol. 2021 Sep 15;339:243-245. doi: 10.1016/j.ijcard.2021.07.031. |
| 39. | D'Erasmo L, Gallo A, Cefalù AB, Di Costanzo A, Saheb S, Giammanco A, Averna M, Buonaiuto A, Iannuzzo G, Fortunato G, Puja A, Montalcini T, Pavanello C, Calabresi L, Vigna GB, Bucci M, Bonomo K, Nota F, Sampietro T, Sbrana F, Suppressa P, Sabbà C, Fimiani F, **Cesaro A,** Calabrò P, Palmisano S, D'Addato S, Pisciotta L, Bertolini S, Bittar R, Kalmykova O, Béliard S, Carrié A, Arca M, Bruckert E. *Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.* Orphanet J Rare Dis. 2021 Sep 8;16(1):381. doi: 10.1186/s13023-021-01999-8. |
| 40. | Monda E, Lioncino M, Pacileo R, Rubino M, Cirillo A, Fusco A, Esposito A, Verrillo F, Di Fraia F, Mauriello A, Tessitore V, Caiazza M, **Cesaro A,** Calabrò P, Russo MG, Limongelli G. *Advanced Heart Failure in Special Population-Pediatric Age.*<br>Heart Fail Clin. 2021 Oct;17(4):673-683. doi: 10.1016/j.hfc.2021.05.011. |
| 41. | Galiero R, Caturano A, Vetrano E, **Cesaro A**, Rinaldi L, Salvatore T, Marfella R, Sardu C, Moscarella E, Gragnano F, Calabrò P, Sasso FC. *Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease.* Rev Cardiovasc Med . 2021 Sep 24;22(3):755-768 |
| 42. | Calabrò P, Gragnano F, Niccoli G, Marcucci R, Zimarino M, Spaccarotella C, Renda G, Patti G, Andò G, Moscarella E, Mancone M, **Cesaro A**, Giustino G, De Caterina R, Mehran R, Capodanno D, Valgimigli M, Windecker S, Dangas GD, Indolfi C, Angiolillo DJ. *Antithrombotic Therapy in Patients Undergoing Transcatheter* |

| | |
|---|---|
| | *Interventions for Structural Heart Disease.* Circulation. 2021 Oct 19;144(16):1323-1343. |
| 43. | **Cesaro A**, Gragnano F, Calabrò P, Moscarella E, Santelli F, Fimiani F, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Pelliccia F, Bossone E, Pengo V, Gresele P, Marcucci R; START-ANTIPLATELET collaborators. *Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry.* Int J Cardiol. 2021 Oct 23:S0167-5273(21)01692-2 |
| 44. | **Cesaro A,** Fimiani F, Gragnano F, Moscarella E, Schiavo A, Vergara A, Akioyamen L, D'Erasmo L, Averna M, Arca M, Calabrò P. *New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia.* Heart Fail Clin. 2022 Jan;18(1):177-188. doi: 10.1016/j.hfc.2021.07.008. |
| 45. | Rubino M, Monda E, Lioncino M, Caiazza M, Palmiero G, Dongiglio F, Fusco A, Cirillo A, **Cesaro A**, Capodicasa L, Mazzella M, Chiosi F, Orabona P, Bossone E, Calabrò P, Pisani A, Germain DP, Biagini E, Pieroni M, Limongelli G. *Diagnosis and Management of Cardiovascular Involvement in Fabry Disease.* Heart Fail Clin. 2022 Jan;18(1):39-49. doi: 10.1016/j.hfc.2021.07.005. |
| 46. | Brancaccio M, Mennitti C, **Cesaro A,** Monda E, D'Argenio V, Casaburi G, Mazzaccara C, Ranieri A, Fimiani F, Barretta F, Uomo F, Caiazza M, Lioncino M, D'Alicandro G, Limongelli G, Calabrò P, Terracciano D, Lombardo B, Frisso G, Scudiero O. *Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge*. Diagnostics (Basel). 2021 Nov 19;11(11):2144. doi: 10.3390/diagnostics11112144. |
| 47. | Brancaccio M, Mennitti C, **Cesaro A,** Fimiani F, Vano M, Gargiulo B, Caiazza M, Amodio F, Coto I, D'Alicandro G, Mazzaccara C, Lombardo B, Pero R, Terracciano D, Limongelli G, Calabrò P, D'Argenio V, Frisso G, Scudiero O. *The Biological Role of Vitamins in Athletes' Muscle, Heart and Microbiota.* Int J Environ Res Public Health. 2022 Jan 23;19(3):1249. doi: 10.3390/ijerph19031249. |
| 48. | Gragnano F, **Cesaro A,** Pelliccia F, Limongelli G. *Early-onset MINOCA: Prognostic implications and considerations for practice*. Int J Cardiol. 2022 May 1;354:14-16. doi: 10.1016/j.ijcard.2022.03.015. |
| 49. | Gragnano F, **Cesaro A,** Calabrò P. *Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications.* Curr Vasc Pharmacol. 2022 Apr 13. doi: 10.2174/1570161120666220413094635 |
| 50. | Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, **Cesaro A**, Gragnano F, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Casella G, Mauro C, Vassilev D, Marfella R, Calabrò P, Barbato E, Pizzi C. *Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.* Cardiovasc Diabetol. 2022 May 15;21(1):77. doi: 10.1186/s12933-022-01506-8. |

| | |
|---|---|
| 51. | Akkaif MA, Sha'aban A**, Cesaro A**, Jaber AAS, Vergara A, Yunusa I, Jatau AI, Mohammed M, Govindasamy GS, Al-Mansoub MA, Sheikh Abdul Kader MA, Ibrahim B.*The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.* Inflammopharmacology. 2022 Aug;30(4):1143-1151. doi: 10.1007/s10787-022-01009-8. |
| 52. | Pelliccia F, Gragnano F, Pasceri V, **Cesaro A**, Zimarino M, Calabrò P. *Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention.* J Clin Med. 2022 Jun 21;11(13):3574. doi: 10.3390/jcm11133574. |
| 53. | Abrignani MG, Maloberti A, Temporelli PL, Binaghi G, **Cesaro A**, Ciccirillo F, Oliva F, Gabrielli D, Riccio C, Gulizia MM, Colivicchi F. *[Long COVID: nosographic aspects and clinical epidemiology].* G Ital Cardiol (Rome). 2022 Sep;23(9):651-662. doi: 10.1714/3860.38447. |
| 54. | Gragnano F, Pelliccia F, **Cesaro A**, Calabrò P. *Geographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES trial.* Int J Cardiol. 2023 Jan 15;371:132-134. doi: 10.1016/j.ijcard.2022.09.003. Epub 2022 Sep 9. |
| 55. | Akkaif MA, Bitar AN, Al-Kaif LAIK, Daud NAA, Sha'aban A, Noor DAM, Abd Aziz F, **Cesaro A**, Sk Abdul Kader MA, Abdul Wahab MJ, Khaw CS, Ibrahim B *The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia.* J Cardiovasc Dev Dis. 2022 Sep 16;9(9):307. doi: 10.3390/jcdd9090307. |
| 56. | Sciahbasi A, Gargiulo G, Talarico GP, **Cesaro A**, Zilio F, De Rosa S, Talanas G, Tebaldi M, Andò G, Rigattieri S, Misuraca L, Cortese B, Imperadore F, Lucci V, Guiducci V, Renda G, Zezza L, Versaci F, Giannico MB, Caruso M, Spaccarotella C, Calabrò P, Esposito G, Tarantini G, Musumeci G, Rubboli A. *Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent.* J Cardiovasc Med (Hagerstown). 2022 Nov 1;23(11):738-743. doi: 10.2459/JCM.0000000000001372. Epub 2022 Sep 7. |
| 57. | **Cesaro A**, Gragnano F, Paolisso P, Bergamaschi L, Gallinoro E, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Oreglia JA, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Pizzi C, Barbato E, Calabrò P, Marfella R. *In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study.* Front Cardiovasc Med. 2022 Sep 27;9:1012220. doi: 10.3389/fcvm.2022.1012220. eCollection 2022 |
| 58. | Gragnano F, Capolongo A, Terracciano F, Gargiulo G, De Sio V, **Cesaro A**, Moscarella E, Patti G, Porto I, Esposito G, Angiolillo DJ, Calabrò P *Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice* J Clin Med. 2022 Oct 23;11(21):6246. doi: 10.3390/jcm11216246 |
| 59. | **Cesaro A**, Acerbo V, Raucci G, Calabrò P *Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?* Eur Heart J Suppl. 2022 Nov 12;24(Suppl I):I34-I37. doi: 10.1093/eurheartjsupp/suac099. eCollection 2022 Nov. |
| 60. | Patti G, Cavallari I, **Cesaro A**, Gragnano F, Riva L, Fimiani F, Cuccia C, Fresco C, Calabrò P, Leonardi S, Marcucci R, Rubboli A. *Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology.* |

| | |
|---|---|
| | Vascul Pharmacol. 2023 Feb;148:107137. doi: 10.1016/j.vph.2022.107137. Epub 2022 Dec 1. |
| 61. | Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, **Cesaro A**, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E<br>*Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.* Pharmacol Res. 2023 Jan;187:106597. doi: 10.1016/j.phrs.2022.106597. Epub 2022 Dec 5. |
| 62. | **Cesaro A**, De Michele G, Gragnano F, Calabrò P<br>*How has COVID-19 impacted the care of patients with acute coronary syndromes? Expert Rev Cardiovasc Ther. 2023 Jan;21(1):1-4. doi: 10.1080/14779072.2023.2159809. Epub 2022 Dec 26* |
| 63. | Mennitti C, Ranieri A, Nigro E, Tripodi L, Brancaccio M, Ulisse J, Gentile L, Fimiani F, **Cesaro A**, D'Alicandro G, Limongelli G, Daniele A, Pero R, Frisso G, Calabrò P, Pastore L, Licenziati MR, Scudiero O, Lombardo B.*The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers*. Int J Environ Res Public Health. 2022 Dec 29;20(1):602. doi: 10.3390/ijerph20010602. |
| 64. | Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, **Cesaro A**, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Barbato E, Pizzi C *Reply to SGLT-2 inhibitors: Post-infarction interventional effects.* Pharmacol Res. 2023 Mar;189:106664. doi: 10.1016/j.phrs.2023.106664. Epub 2023 Jan 13. |
| 65. | Gargiulo P, Basile C, **Cesaro A**, Marzano F, Buonocore D, Asile G, Abbate V, Vicidomini F, Paolillo S, Spaccarotella CAM, Catalano A, Spirito G, Merlini PA, Maloberti A, Iannuzzo G, Ciccone MM, Zito AP, Paloscia L, D'Alleva A, Varbella F, Corleto A, Brunetti ND, Corbo MD, Calabrò P, Indolfi C, Perrone-Filardi P.<br>*Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT)* Atherosclerosis. 2023 Feb;366:32-39. doi: 10.1016/j.atherosclerosis.2023.01.001. Epub 2023 Jan 13 |
| 66. | Gragnano F, Capolongo A, Terracciano F, Gargiulo G, **Cesaro A**, Moscarella E, De Sio V, Patti G, Porto I, Esposito G, Calabrò P.*[New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention].* G Ital Cardiol (Rome). 2023 Feb;24(2):99-109. doi: 10.1714/3963.39417 |
| 67. | Marfella R, Sardu C, D'Onofrio N, Fumagalli C, Scisciola L, Sasso FC, Siniscalchi M, Marfella LV, D'Andrea D, Minicucci F, Signoriello G, **Cesaro A**, Trotta MC, Frigé C, Prattichizzo F, Balestrieri ML, Ceriello A, Calabrò P, Mauro C, Del Viscovo L, Paolisso G *SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes.* BMC Med. 2023 Feb 24;21(1):71. doi: 10.1186/s12916-023-02781-2 |
| 68. | Monda E, Lioncino M, Verrillo F, Rubino M, Caiazza M, Mauriello A, Guarnaccia N, Fusco A, Cirillo A, Covino S, Altobelli I, Diana G, Palmiero G, Dongiglio F, Natale F, **Cesaro A**, Bossone E, Russo MG, Calabrò P, Limongelli G. *The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases*<br>Diagnostics (Basel). 2023 Feb 17;13(4):772. doi: 10.3390/diagnostics13040772. |

| | |
|---|---|
| 69. | Monda E, Rubino M, Palmiero G, Verrillo F, Lioncino M, Diana G, Cirillo A, Fusco A, Dongiglio F, Caiazza M, Altobelli I, Mauriello A, Guarnaccia N, Scatteia A, **Cesaro A**, Pacileo G, Sarubbi B, Frisso G, Bauce B, D'Andrea A, Dellegrottaglie S, Russo MG, Calabrò P, Limongelli G. *Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy.* J Clin Med. 2023 Feb 16;12(4):1568. doi: 10.3390/jcm12041568 |
| 70. | Cuomo G, Iannone FP, Di Lorenzo A, Testa C, Ciccarelli M, Venturini E, **Cesaro A**, Pacileo M, Tagliamonte E, D'Andrea A, Vecchione C, Vigorito C, Giallauria F. *Potential Role of Global Longitudinal Strain in Cardiac and Oncological Patients Undergoing Cardio-Oncology Rehabilitation (CORE).* Clin Pract. 2023 Mar 7;13(2):384-397. doi: 10.3390/clinpract13020035. |
| 71. | Ciccirillo F, Abrignani MG, Temporelli PL, Binaghi G, Cappelletto C, Lopriore V, **Cesaro A**, Maloberti A, Cozzoli D, Riccio C, Caldarola P, Oliva F, Gabrielli D, Colivicchi F. *The Key Role of a Psychoactive Substance Use History in Comprehensive Cardiovascular Risk Assessment, Diagnosis, Treatment, and Prevention.* Cardiology. 2023;148(3):257-268. doi: 10.1159/000530246. Epub 2023 Apr 11. |
| 72. | Calabrò P, Spaccarotella C, **Cesaro A**, Andò G, Piccolo R, De Rosa S, Zimarino M, Mancone M, Gragnano F, Moscarella E, Muscoli S, Romeo F, Barillà F, Filardi PP, Indolfi C, Niccoli G; Interventional Cardiology Working Group of Italian Society of Cardiology. *Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology.* J Cardiovasc Med (Hagerstown). 2023 Apr 1;24(Suppl 1):e86-e94. doi: 10.2459/JCM.0000000000001440 |
| 73. | Palmiero G, **Cesaro A**, Galiero R, Loffredo G, Caturano A, Vetrano E, Rinaldi L, Salvatore T, Ruggiero R, Rosaria Di Palo M, Sardu C, Marfella R, Limongelli G, Calabrò P, Carlo Sasso F. *Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study.* Diabetes Res Clin Pract. 2023 Jun;200:110686. doi: 10.1016/j.diabres.2023.110686. Epub 2023 Apr 25. |
| 74. | Gragnano F, Pelliccia F, Guarnaccia N, Niccoli G, De Rosa S, Piccolo R, Moscarella E, Fabris E, Montone RA, **Cesaro A**, Porto I, Indolfi C, Sinagra G, Perrone Filardi P, Andò G, Calabrò P; Working Group of Interventional Cardiology of the Italian Society of Cardiology. *Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective.* J Clin Med. 2023 Apr 11;12(8):2810. doi: 10.3390/jcm12082810. |
| 75. | **Cesaro A**, Acerbo V, Vetrano E, Signore G, Scherillo G, Rotolo FP, De Michele G, Scialla F, Raucci G, Panico D, Gragnano F, Moscarella E, Galiero R, Caturano A, Ruggiero R, Sasso FC, Calabrò P. *Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice.* Int J Mol Sci. 2023 Apr 30;24(9):8099. doi: 10.3390/ijms24098099. |
| 76. | Ciccarelli M, Giallauria F, Carrizzo A, Visco V, Silverio A, **Cesaro A**, Calabrò P, De Luca N, Mancusi C, Masarone D, Pacileo G, Tourkmani N, Vigorito C, Vecchione C. *Artificial intelligence in cardiovascular prevention: new ways will open new doors* J Cardiovasc Med (Hagerstown). 2023 May 1;24(Suppl 2):e106-e115. doi: 10.2459/JCM.0000000000001431. |

| | |
|---|---|
| 77. | Cimmino G, Muscoli S, De Rosa S, **Cesaro A**, Perrone MA, Selvaggio S, Selvaggio G, Aimo A, Pedrinelli R, Mercuro G, Romeo F, Perrone Filardi P, Indolfi C, Coronelli M; Pathogenesis Of Atherosclerosis Working Group Of The Italian Society Of Cardiology. *Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation.*<br>J Cardiovasc Med (Hagerstown). 2023 May 1;24(Suppl 2):e156-e167. doi: 10.2459/JCM.0000000000001450. |
| 78. | Abrignani MG, Ciccirillo F, Temporelli PL, **Cesaro A**, Binaghi G, Maloberti A, Cappelletto C, Oliva F, Riccio C, Caldarola P, Gabrielli D, Colivicchi F. [*Substances of abuse and cardiovascular risk: cannabinoids].*<br>G Ital Cardiol (Rome). 2023 Jun;24(6):455-465. doi: 10.1714/4041.40205 |
| 79. | Gragnano F, Capolongo A, Terracciano F, De Sio V, Maddaluna P, Fimiani F, Moscarella E, **Cesaro A**, Montone RA, Bianco R, Lisi D, Mensorio MM, Annecchiarico A, Calabrò P. *De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine.*<br>Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(7):545-551. doi: 10.1080/14779072.2023.2221851. Epub 2023 Jun 5. |
| 80. | Paolisso P, Bergamaschi L, Cesaro A, Gallinoro E, Gragnano F, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Belmonte M, Esposito G, Morici N, Andrea Oreglia J, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Calabrò P, Barbato E, Marfella R, Pizzi C. *Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry.*<br>Diabetes Res Clin Pract. 2023 Aug;202:110766. doi: 10.1016/j.diabres.2023.110766. Epub 2023 Jun 3. |
| 81. | Marfella R, Prattichizzo F, Sardu C, Paolisso P, D'Onofrio N, Scisciola L, La Grotta R, Frigé C, Ferraraccio F, Panarese I, Fanelli M, Modugno P, Calafiore AM, Melchionna M, Sasso FC, Furbatto F, D'Andrea D, Siniscalchi M, Mauro C, **Cesaro A**, Calabrò P, Santulli G, Balestrieri ML, Barbato E, Ceriello A, Paolisso G. *Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque.* Atherosclerosis. 2023 Aug;378:117180. doi: 10.1016/j.atherosclerosis.2023.06.971. Epub 2023 Jun 29. |
| 82. | Acerbo V, **Cesaro A**, Scherillo G, Signore G, Rotolo FP, De Michele G, Scialla F, Raucci G, Panico D, Fimiani F, Moscarella E, Gragnano F, Calabrò P. *Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease.*<br>Heart Fail Rev. 2023 Nov;28(6):1325-1334. doi: 10.1007/s10741-023-10335-0. Epub 2023 Jul 26. |
| 83. | **Cesaro A**, De Michele G, Fimiani F, Acerbo V, Scherillo G, Signore G, Rotolo FP, Scialla F, Raucci G, Panico D, Gragnano F, Moscarella E, Scudiero O, Mennitti C, Calabrò P. *Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options.*<br>Front Cardiovasc Med. 2023 Jul 27;10:1187735. doi: 10.3389/fcvm.2023.1187735. eCollection 2023. |
| 84. | Vergara A, De Felice M, **Cesaro A**, Gragnano F, Pariggiano I, Golia E, De Pasquale A, Blasi E, Fimiani F, Monda E, Limongelli G, Calabrò P. *Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go.* |

| | |
|---|---|
| | Angiology. 2023 Sep 12:33197231201929. doi: 10.1177/00033197231201929. Online ahead of print. |
| 85. | Vergara A, De Felice M, **Cesaro A**, Gragnano F, Pariggiano I, Golia E, De Pasquale A, Blasi E, Fimiani F, Monda E, Limongelli G, Calabrò P. *Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go.* Angiology. 2023 Sep 12:33197231201929. doi: 10.1177/00033197231201929. Online ahead of print. |

## 5.1 Book chapters

"Epidemiologia e prevenzione" in "Cardiologia per studenti e medici di medicina generale" (Idelson Gnocchi, 2020)

## 6.Varia

## 6.1 Membership:

Regular member of the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)
Member of Chronic Cardiovascular Disease Working Group of ANMCO

Regular member of the Italian Society of Cardiology (SIC)

Fellow of Italian Society of Cardiology (SIC) - FISC

Regular member of the Italian Federation of Cardiology (FIC)

Regular member of the Interventional Cardiology Working Group of the SIC

Regular member of Thrombosis Working Group of the SIC

Regular member of Atherosclerosis Working Group of the SIC

Regualar member of Società Italiana di Ecocardiografia e CardioVascular Imaging (SIECVI)

Professional member of European Society of Cardiology (ESC)

Regular member of European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Regular member of European Association of Preventive Cardiology (EAPC)

Regular member of the ESC Council for Cardiology Practice

Regular member of the ESC Council on Hypertension

Regular member of the ESC Council on Stroke

Regular member of the ESC Council on Valvular Heart Disease

Regular member of the Italian Society of Atherosclerosis (SISA)

Regional executive board member - Campania section - Italian Society of Atherosclerosis (SISA)

Regular member of European Atherosclerosis Society (EAS)

I authorize the use of my personal data according to Italian D.L. 196/2003 and 679/2016 or “GDPR”

I authorize the treatment of personal data and I declare the truthfulness of the data according to Italian D.P.R. n.445/2000

Caserta,16-OCT-2023